MedTrace Logo

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

NCT00785044 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 471

Last updated 2017-04-26

Study results available
· View outcomes & findings →

Summary

The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

I-123 mIBG

This was an observational study. Participants were previously dosed in separate study.

Sponsors & Collaborators

  • GE Healthcare

    lead INDUSTRY

Principal Investigators

  • John Strohmeyer · GE Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-01-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785044 on ClinicalTrials.gov